27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The first single-stage individual patient data meta-analysis from randomized double-blind placebo-controlled clinical trials provides evidence to support benefits of antihypertensive treatment in late-mid and later life to lower the risk of dementia. 5 key findings →
Design: meta-analysis Participants: 28,008 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Main results We included two trials with 26,340 participants aged 40 to 82 years of whom 11,610 were aged 70 or older. 2 key findings →
Design: meta-analysis Participants: 26,340 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Evidence from well-planned, representative epidemiological surveys is scarce in many regions. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A nurse-led, multidomain intervention did not result in a reduced incidence of all-cause dementia in an unselected population of older people. 3 key findings →
Design: randomized controlled trial Participants: 3,526 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this sample of 101 219 patients, 52.7% were women and mean age was 62.6 years (SD, 9.3 years) as of November 1, 2016. 2 key findings →
Design: cohort Participants: 101,219 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia represents a substantial financial burden on society, one that is similar to the financial burden of heart disease and cancer. 3 key findings →
Design: longitudinal study Participants: 856 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The detailed estimates in this study constitute the best current basis for policymaking, planning, and allocation of health and welfare resources in dementia care. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 95 unique studies were included in this systematic review, of which 74 with 2 760 379 unique patients were also included in 5-year age band meta-analyses. 5 key findings →
Design: systematic review Participants: 95 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Antipsychotic use compared with non-use in adults with dementia was associated with increased risks of stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia, and acute kidney injury, but not ventricular arrhythmia. 5 key findings →
Design: cohort Participants: 173,910 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
An estimated 8.8 million Indians older than 60 years have dementia. 2 key findings →
Design: longitudinal study Participants: 2,528 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Main results Seventeen trials with 1067 participants met the inclusion criteria. 5 key findings →
Design: meta-analysis Participants: 1,067 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Neurotropic herpesviruses may be implicated in the development of dementia 1-5 . 1 key finding →
Design: cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher Hcy levels, lower educational attainment, and decreased physical activity were particularly strong predictors of incident AD. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This systematic review and meta-analyses covering a wide range of observational studies and diverse settings provides robust support for the CR hypothesis. 5 key findings →
Design: systematic review Participants: 437,477 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We aimed to determine the effect of live attenuated herpes zoster vaccination on incident dementia diagnoses among people aged 70 years and older using a natural experiment in Ontario, Canada, and to triangulate these findings, using a second natural experiment in Ontario and a quasi-experimental approach that uses data from multiple Canadian provinces. 3 key findings →
Design: cohort Participants: 232,124 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study findings suggest delirium was a strong risk factor for death and incident dementia among older adult patients. 3 key findings →
Design: cohort Participants: 110,422 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
4024 articles were identified, and 74 were included in our narrative synthesis. 2 key findings →
Design: meta-analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest medication-specific educational mailings targeting patients with AD or ADRD and their clinicians are not effective in reducing the use of high-risk medications. 4 key findings →
Design: open-label trial Participants: 787 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss is independently associated with incident all-cause dementia. 4 key findings →
Design: longitudinal study Participants: 639 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Being married is associated with reduced risk of dementia than widowed and lifelong single people, who are also underdiagnosed in routine clinical practice. 5 key findings →
Design: systematic review Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Variation in service use among sites was most plausibly accounted for by stark differences in the extent of out-of-pocket expenses, and the ability of older people and their families to afford them. 3 key findings →
Design: meta-analysis Participants: 17,944 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The study cohorts had an average age of 75.0 years (95% CI, 74.8-75.2 years) in 2000 and 74.8 years (95% CI, 74.5-75.1 years) in 2012 (P = .24); 58.4% (95% CI, 57.3%-59.4%) of the 2000 cohort was female compared with 56.3% (95% CI, 55.5%-57.0%) of the 2012 cohort (P Conclusions and relevance The prevalence of dementia in the United States declined significantly between 2000 and 2012. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sensitivity analyses suggest that these estimates are robust to the change in response. 2 key findings →
Participants: 2,500 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Differential diagnosis of dementia remains a challenge in neurology due to symptom overlap across etiologies, yet it is crucial for formulating early, personalized management strategies. 1 key finding →
Participants: 51,269 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared with the usual care clinics (12-month incidence, 213 of 1724 [12.4%]), the odds of an incident ADRD diagnosis were higher in the clinics randomized to QDRS plus PDM (12-month incidence, 355 of 2301 [15.4%]; adjusted odds ratio [AOR], 1.31; 95% CI, 1.05-1.64) but not the clinics randomized to PDM only (12-month incidence, 134 of 1300 [10.3%]; AOR, 0.84; 95% CI, 0.63-1.11]). 3 key findings →
Design: RCT Participants: 5,325 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →